Company news

Cosmos Health Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

June 8, 2026

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

June 5, 2026

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

June 3, 2026

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

June 3, 2026

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

June 2, 2026

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

June 1, 2026

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

May 26, 2026

Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants

May 21, 2026

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

May 21, 2026

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

May 13, 2026

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

May 11, 2026

Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness

May 5, 2026

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

April 30, 2026

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

April 20, 2026

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

April 20, 2026

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

April 17, 2026

Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%

April 16, 2026

Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments

April 15, 2026

Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units

April 12, 2026

Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months

April 9, 2026

COSM Announces Liver Health Product with Large Upside Potential

April 9, 2026

Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction

April 7, 2026

Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets

March 31, 2026

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

March 19, 2026

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Proje...

March 18, 2026

Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

March 10, 2026

Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

March 9, 2026

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

February 24, 2026

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

February 19, 2026

Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer

February 18, 2026

Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK’s Second-Largest Beauty and Health Retailer

February 17, 2026

Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026

February 17, 2026

Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies

February 10, 2026

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

January 20, 2026

Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

January 13, 2026

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

January 5, 2026

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

December 24, 2025

Cosmos Health is Forcing the Market to Reframe the Conversation

December 19, 2025

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

December 2, 2025

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases

December 2, 2025

Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M

November 16, 2025

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy

October 31, 2025

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

October 20, 2025

Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 16, 2025

Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million

October 12, 2025

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

October 10, 2025

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

October 3, 2025

Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation

September 28, 2025

Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

September 24, 2025

Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue

September 22, 2025

← Newer news releases · Older news releases →

Decks